Simple Summary Liver cancer is one of the most difficult solid tumors to treat and is
responsible for one-third of cancer-related deaths worldwide. In particular, the quest for …

Immune checkpoint inhibitors (ICIs) have emerged as effective therapeutics for multiple
cancers. Nevertheless, as immunotherapeutic approaches are being extensively utilized …

Metabolic derivatives of numerous microorganisms inhabiting the human gut can participate
in physiological activities and immune status of the lungs through the gut-lung axis. The …

Hepatocellular carcinoma (HCC) is a highly aggressive malignant tumor with limited
treatment options and poor prognosis. In this study, we reveal the pivotal role of Stratifin …

Hepatocellular carcinoma (HCC) is the third leading cause of global cancer-related deaths.
Despite immunotherapy offering hope for patients with HCC, only some respond to it …

Tumor micronecrosis is a pathological feature that reflects malignant biological behavior in
hepatocellular carcinoma (HCC). However, whether micronecrosis can optimize HCC …

A high mortality rate makes hepatocellular carcinoma (HCC) a difficult cancer to treat. When
surgery is not possible, liver cancer patients are treated with chemotherapy. However, HCC …

Immune therapy has significantly improved the prognosis of hepatocellular carcinoma
(HCC) patients, yet its efficacy remains limited, underscoring the urgency to identify new …

Primary liver cancer, represented mainly by hepatocellular carcinoma (HCC) and
intrahepatic cholangiocellular carcinoma (CCA), is one of the most common and deadliest …

Immunotherapy has emerged as the primary treatment modality for patients with advanced
Hepatocellular carcinoma (HCC). However, its clinical efficacy remains limited, benefiting …